AUTHOR=Willems Laurent M. , Bertsche Astrid , Bösebeck Frank , Hornemann Frauke , Immisch Ilka , Klein Karl M. , Knake Susanne , Kunz Rhina , Kurlemann Gerhard , Langenbruch Lisa , Möddel Gabriel , Müller-Schlüter Karen , von Podewils Felix , Reif Philipp S. , Steinhoff Bernhard J. , Steinig Isabel , Rosenow Felix , Schubert-Bast Susanne , Strzelczyk Adam 

TITLE=Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany

JOURNAL=Frontiers in Neurology

VOLUME=9

YEAR=2018

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2018.00569

DOI=10.3389/fneur.2018.00569

ISSN=1664-2295

ABSTRACT=<p><bold>Objective:</bold> To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).</p><p><bold>Method:</bold> A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.</p><p><bold>Results:</bold> Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (<italic>n</italic> = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (<italic>n</italic> = 4; 9%) or 50% (<italic>n</italic> = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.</p><p><bold>Significance:</bold> In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.</p>